Sarepta Therapeutics (SRPT) EBT (2010 - 2026)

Sarepta Therapeutics' EBT history runs 17 years deep, the most recent figure standing at $343.2 million for Q1 2026.

• In Q1 2026, EBT rose 189.48% year-over-year to $343.2 million; the TTM figure through Mar 2026 stood at $24.5 million (up 109.55% YoY), while the FY2025 annual figure was -$702.2 million, down 516.34% from the prior year.
• EBT was $343.2 million for Q1 2026 at Sarepta Therapeutics, up from -$278.3 million in the prior quarter.
• In the past five years, EBT ranged from a high of $343.2 million in Q1 2026 to a low of -$512.7 million in Q1 2023.
• Historically, EBT has averaged -$42.5 million across 5 years, with a median of -$14.6 million in 2023.
• Biggest YoY gain for EBT was 1031.6% in 2025; the steepest drop was 1025.3% in 2025.
• A 5-year view of EBT shows it stood at $337.3 million in 2022, then dropped by 17.27% to $279.0 million in 2023, then tumbled by 71.46% to $79.6 million in 2024, then tumbled by 449.46% to -$278.3 million in 2025, then surged by 223.31% to $343.2 million in 2026.
• The last three EBT figures came in at $343.2 million (Q1 2026), -$278.3 million (Q4 2025), and -$194.0 million (Q3 2025), per Business Quant data.